TP53 and neoplasm: Non-small cell lung cancer: Forty-eight NSCLC tumor samples tested by the comprehensive panel also showed high frequency of variants in KRAS (31.2%) and TP53 (18.7%) genes, which was in line with the targeted lung subpanel.